JP2017514877A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514877A5
JP2017514877A5 JP2016567002A JP2016567002A JP2017514877A5 JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5 JP 2016567002 A JP2016567002 A JP 2016567002A JP 2016567002 A JP2016567002 A JP 2016567002A JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5
Authority
JP
Japan
Prior art keywords
methoxycyclopent
group
similarly
described below
same structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514877A (ja
JP6505131B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2015/051312 external-priority patent/WO2015170081A1/en
Publication of JP2017514877A publication Critical patent/JP2017514877A/ja
Publication of JP2017514877A5 publication Critical patent/JP2017514877A5/ja
Application granted granted Critical
Publication of JP6505131B2 publication Critical patent/JP6505131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567002A 2014-05-08 2015-05-05 イミダゾ[4,5−c]キノリン−2−オン化合物および癌の処置におけるそれらの使用 Active JP6505131B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
US61/990,232 2014-05-08
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2017514877A JP2017514877A (ja) 2017-06-08
JP2017514877A5 true JP2017514877A5 (enExample) 2018-06-14
JP6505131B2 JP6505131B2 (ja) 2019-04-24

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567002A Active JP6505131B2 (ja) 2014-05-08 2015-05-05 イミダゾ[4,5−c]キノリン−2−オン化合物および癌の処置におけるそれらの使用

Country Status (39)

Country Link
US (4) US9428503B2 (enExample)
EP (1) EP3140303B1 (enExample)
JP (1) JP6505131B2 (enExample)
KR (1) KR102013021B1 (enExample)
CN (1) CN106255692B (enExample)
AP (1) AP2016009532A0 (enExample)
AR (1) AR100340A1 (enExample)
AU (1) AU2015257456B2 (enExample)
CA (1) CA2946459C (enExample)
CL (1) CL2016002735A1 (enExample)
CR (1) CR20160523A (enExample)
CY (1) CY1120248T1 (enExample)
DK (1) DK3140303T3 (enExample)
DO (1) DOP2016000281A (enExample)
EA (1) EA031674B1 (enExample)
ES (1) ES2670416T3 (enExample)
HR (1) HRP20180697T1 (enExample)
HU (1) HUE037558T2 (enExample)
IL (1) IL248397B (enExample)
LT (1) LT3140303T (enExample)
MA (1) MA39960A (enExample)
MX (1) MX374401B (enExample)
NI (1) NI201600166A (enExample)
NO (1) NO2714752T3 (enExample)
NZ (1) NZ726042A (enExample)
PE (1) PE20170403A1 (enExample)
PH (1) PH12016502168A1 (enExample)
PL (1) PL3140303T3 (enExample)
PT (1) PT3140303T (enExample)
RS (1) RS57223B1 (enExample)
SG (1) SG11201609164VA (enExample)
SI (1) SI3140303T1 (enExample)
SM (1) SMT201800259T1 (enExample)
SV (1) SV2016005312A (enExample)
TN (1) TN2016000458A1 (enExample)
TR (1) TR201807101T4 (enExample)
TW (1) TWI662034B (enExample)
UY (1) UY36112A (enExample)
WO (1) WO2015170081A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107889488B (zh) * 2015-04-02 2020-08-11 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP4071174A1 (en) * 2016-02-15 2022-10-12 AstraZeneca AB Methods comprising fixed intermittent dosing of cediranib
JP2019512512A (ja) * 2016-03-21 2019-05-16 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag シンノリン−4−アミン化合物およびその癌治療への使用
US20190119270A1 (en) * 2016-04-07 2019-04-25 Astrazeneca Ab N-Oxide Compound and Its Use in Treating Cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
LT3558997T (lt) 2016-12-20 2021-04-26 Astrazeneca Ab Aminotriazolopiridino junginiai ir jų naudojimas vėžio gydymui
KR102660196B1 (ko) 2017-01-09 2024-04-24 임팩트 테라퓨틱스 (상하이), 인코포레이티드 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
US11547703B2 (en) 2017-02-27 2023-01-10 Impact Therapeutics (Shanghai), Inc Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
US12226414B2 (en) * 2018-09-14 2025-02-18 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (ATM) kinase and uses thereof
EP3866785A1 (en) * 2018-10-15 2021-08-25 Merck Patent GmbH Combination therapy utilizing dna alkylating agents and atr inhibitors
WO2020178282A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
WO2021004482A1 (zh) * 2019-07-10 2021-01-14 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
EP4028400A4 (en) * 2019-09-12 2023-09-06 Impact Therapeutics (Shanghai), Inc SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND THEIR USES
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021146127A1 (en) * 2020-01-13 2021-07-22 Zhanggui Wu Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment
TW202216209A (zh) * 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN117015534A (zh) * 2021-02-03 2023-11-07 艾科思莱德制药公司 用于癌症疗法的双重atm和dna-pk抑制剂以及免疫治疗剂的组合
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
KR20060117329A (ko) 2003-11-21 2006-11-16 노파르티스 아게 단백질 키나제 저해제로서의 1h-이미다조퀴놀린 유도체
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
EP2356120B1 (en) 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
NZ596487A (en) 2009-06-04 2012-11-30 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
US20100311714A1 (en) * 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
EP2483277B1 (en) * 2009-09-28 2015-12-02 F. Hoffmann-La Roche AG Benzoxepin pi3k inhibitor compounds and methods of use
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
JPWO2012026233A1 (ja) 2010-08-26 2013-10-28 日立建機株式会社 建設機械
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CA2819955A1 (en) 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Similar Documents

Publication Publication Date Title
JP2017514877A5 (enExample)
JP2017107167A5 (enExample)
JP2017016753A5 (enExample)
JP2014179090A5 (enExample)
JP2017059339A5 (enExample)
JP2015077594A5 (enExample)
JP2016526891A5 (enExample)
JP2017069240A5 (enExample)
JP2017528346A5 (enExample)
JP2017528401A5 (enExample)
JP2017179103A5 (enExample)
JP2016169268A5 (enExample)
JP2017509780A5 (enExample)
JP2016069397A5 (enExample)
JP2017203885A5 (enExample)
JP2017020017A5 (enExample)
JP2018538325A5 (enExample)
JP2016157119A5 (enExample)
JP2017533170A5 (enExample)
JP2017509782A5 (enExample)
JP2017075254A5 (enExample)
JP2016074795A5 (enExample)
JP2015174850A5 (enExample)
JP2017105890A5 (enExample)
JP2016210942A5 (enExample)